Infinitopes

Join Infinitopes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting today in Houston, where we will be presenting our latest breakthroughs in cancer vaccine discovery and development.   Powered by our AI/ML Precision Immunomics™ antigen discovery platform, we can identify best-in-class pools of hundreds of novel cancer-specific antigens, to empower collaborator’s T-cell & TCR therapies, in addition to our vaccine pipeline. Our lead vaccine candidate ITOP1, is a precision-targeted, immunologically durable, “off-the-shelf” cancer vaccine, designed to prevent recurrence of oesophageal cancer (OC) in patients. ITOP1 has the potential to offer a transformative approach to cancer treatment and will be entering Phase I/IIa clinical development (VISTA study) in H1 '25.    We will be presenting three posters on our pioneering cancer vaccine discovery and development on 8 November, 9am – 7pm CDT:   🔬 Poster #635: ‘A randomised, placebo-controlled, multi-centre Phase I/IIa study evaluating the safety and clinical activity of a novel viral vector cancer vaccine (ITOP1) in patients with resectable oesophageal adenocarcinoma (VISTA study)’ 👩🔬 Poster #1039, recognised as a SITC Top 100 poster: ‘Vaccination with a single dose of a novel delivery platform confers durable >8 month immune responses, with lasting protection against tumour and metastases in preclinical models’ ⚕ Poster #1427: ‘Precision Immunomics™: Identification of hundreds of novel cancer antigens using a sensitive immunopeptidomics-led platform’   Using our integrated ‘right targets, right vectors, right patients, right time’ approach, we are excited to share our latest research as we aim to address unmet clinical need using durably effective therapies to save lives by preventing or significantly delaying disease recurrence for cancer patients.   For more details on our world-leading platforms in precision antigen discovery with vaccine vectors, you can find the full press release on our website and in the comments below.   #Infinitopes #PrecisionMedicine #SITC2024 #Immunotherapy #CancerResearch #CancerVaccine

Exciting News: Infinitopes Wins People's Choice Award at KPMG UK Tech Innovator Final! 🚀 We are thrilled to announce that Infinitopes was awarded the People's Choice Award at the recent KPMG UK Tech Innovator competition! Our CEO, Dr. Jonathan Kwok, had the honor of representing Infinitopes at this incredible event, which brought together some of the UK's most promising tech businesses. It was an inspiring week filled with innovative solutions and groundbreaking ideas in the field of technology, AI, and sustainability. Congratulations to Henrietta Boyd, Co-Founder of Halocycle, on winning the UK Tech Innovator award with their revolutionary approach to reducing plastic waste. We also extend our congratulations to the impressive runners-up, Justin Hughes, CEO at NetZeroNitrogen, and Timothy Pryce, Chair at Cellexcel. A special thank you to the UK final judges: Julia Hoggett, Russ Shaw CBE, Stephen Nundy, Vishal Marria, Elliot Street, and Ezechi Britton MBE, for their time and expertise in evaluating the innovative solutions presented. Josie Hart, Tim Cross, and Tom Fox thank you very much for all your help and support throughout! We are immensely proud to be recognised among such a talented group of innovators and are excited about the future as we continue to push the boundaries of technology in healthcare. #Tech #Innovation #AI #KPMG #TechInnovatorUK #Infinitopes #PeoplesChoiceAward

Join us (virtually) at the 2024 KPMG UK #techinnovatoruk final, streamed live from London tonight! We've been recognised as a #tech trailblazer and are delighted to be a finalist in this year's competition. Save your virtual seat and watch us deliver our pitch here:  https://lnkd.in/eHvmyB_z #TIUK2024

We're thrilled that Infinitopes is a Finalist at KPMG UK's Tech Innovator of the Year 2024. It's super motivating to share what makes our science so special: * RIGHT TARGETS - Precision ImmunomicsTM antigen discovery, for accuracy & safety * RIGHT VECTORS - High efficiency delivery systems, to reliably stimulate durable immune responses, essential to prevent metastases * RIGHT PATIENTS - Prescribed to those most likely to successfully respond * RIGHT TIME - Given at the optimal moments during cancer journeys, to drive enhanced protection through 'epitope spreading' Enormous thanks to our fabulous supporters, including Cancer Research UK (CRUK), Cancer Research Horizons, University of Oxford, Octopus Ventures, Kindred Capital VC, Manta Ray Ventures, Meltwind Advisory LLP, Martlet Capital, Cancer Research Institute (CRI), CRIS Cancer Foundation, Wilbe.com, Saras Capital, HSBC Innovation Banking, OBN (UK) Ltd, BioIndustry Association (BIA), BioEscalator, Wilson Sonsini Goodrich & Rosati & Taylor Wessing, Paul Forster & Vishal Gulati. We couldn't do this without you! Cheer us on as we take the stage at KPMG's HQ in Canary Wharf, July 23rd. We'd welcome you to join us virtually by registering at https://lnkd.in/eHvmyB_z #KPMG #TIUK2024 #techninnovatorUK #SEP2024 #biotech #biotechnology #entrepreneurship #spinouts #cancervaccines #immunotherapy #immunooncology

🌟 Big News! Our CEO, Jonathan Kwok, is set to pitch at KPMG's South Central Regional Heat today. We’re proud to have been shortlisted for KPMG UK’s #techinnovatoruk competition. At Infinitopes, we believe in challenging the status quo and driving meaningful change. We’re excited to present our vision and share how we’re making a difference in the health and biotech industry. Good luck to Jonathan and the other shortlisted nominees presenting today! #TIUK2024 #TechInnovatorUK #WeDareToDisrupt #Innovation #Biotech #KPMG

We are pleased to share our latest publication in Human Vaccines and Immunotherapeutics in which Infinitopes co-authors an invited contribution for the journal’s special addition on cancer vaccines.    The Infinitopes team has amassed a wealth of insight into the fundamental immunology required to develop effective cancer vaccines. Over the past decade, we have crystallised our understanding of the building blocks necessary to design precision-targeted, durably stimulating, affordable vaccine therapies.    Combining insights from previous cancer vaccine clinical development and contemporary knowledge of tumour immunology, in this article we ask: who are the ‘right’ patients, what are the ‘right’ targets, and which are the ‘right’ modalities to maximise the chances of cancer vaccine success?   With thanks to contributors Michael Grant, Lian Ni Lee, Senthil Chinnakannan, Orion Tong, Jonathan Kwok, Nicole Cianci, Luke Tillman, Abhishek Saha, Vinnycius Pereira Almeida, and Carol Leung.   Read the article here: https://lnkd.in/dtYvhsjp

We are extremely proud to announce that Infinitopes has closed a £12.8m seed funding round, which builds on our £2m Biomedical Catalyst award from Innovate UK.   This fundraise brings us one step closer to achieving our mission of saving lives with precision targeted, affordable cancer vaccines. We look forward to utilising this investment to accelerate the development of our cutting-edge cancer vaccines.   Thank you to our investors: Octopus Ventures, who led the round, Cancer Research UK (CRUK), Cancer Research Horizons, Cancer Research Institute (CRI), Kindred Capital VC, Manta Ray Ventures, CRIS Cancer Foundation, Martlet Capital, Meltwind Advisory LLP, Saras Capital, Wilbe | Home for Scientist Leaders and expert angel investors. https://lnkd.in/d4u-4XxV #cancervaccines #cancerresearch #innovation #startups #oxforduniversity

We are extremely proud to announce that Infinitopes has closed a £12.8m seed funding round, which builds on our £2m Biomedical Catalyst award from Innovate UK.   This fundraise brings us one step closer to achieving our mission of saving lives with precision targeted, affordable cancer vaccines. We look forward to utilising this investment to accelerate the development of our cutting-edge cancer vaccines.   Thank you to our investors: Octopus Ventures, who led the round, Cancer Research UK (CRUK), Cancer Research Horizons, Cancer Research Institute (CRI), Kindred Capital VC, Manta Ray Ventures, CRIS Cancer Foundation, Martlet Capital, Meltwind Advisory LLP, Saras Capital, Wilbe | Home for Scientist Leaders and expert angel investors. https://lnkd.in/d4u-4XxV #cancervaccines #cancerresearch #innovation #startups #oxforduniversity

Our brand-new website has just launched! 🚀 Take a look here: https://lnkd.in/dhtwNwWG to meet the team, and discover how Infinitopes is empowering the immune system to fight cancer metastases. Get in touch with us at opportunities@infinitopes.com if you want learn more! #cancervaccines #cancerresearch #innovation #precisionmedicine

Catch our CEO, Dr Jonathan Kwok, and Co-founder and Preclinical VP, Dr Lian Ni Lee at Immuno by Oxford Global #Immuno2024 today where Dr Kwok has kicked off day two with a panel discussion on "Cancer Vaccines As Immuno Therapeutics" alongside Jon Moore and Benoît Van den Eynde. To round off a riveting two days of cutting-edge science, Dr Kwok will be presenting at 2:20 PM on how off-the-shelf precision vaccines can deliver affordable cancer therapies, and guide the conversation to explore mechanisms, platforms and current progress. #OGImmuno #Immuno24 #cancervaccines #cancerresearch #innovation #startups #oxforduniversity